In addition, combinatory, multi-target therapies using a SMN2 exon 7 targeted splice correcting antisense oligonucleotide alongside either a broad spectrum histone deacetylase inhibitor (135) or a protein stabilizing agent (136) have shown additive benefits in cell culture and mouse models for SMA. This evidence concerns the gene SMN2 and proximal spinal muscular atrophy.